Michael Jorrin, "Doc Gumshoe"

Author Bio

Michael Jorrin,
I have been a medical writer for about 25 years; before that I was a documentary film maker, and some of my films were about medical subjects. I am not a physician, but I have a pretty good scientific background. I wouldn’t dream of recommending any kind of treatment to anyone, and I cannot give medical advice. However, I understand the medical literature and the data and evidence behind it, and I have an inquiring and skeptical turn of mind. I scrutinize and question and, sometimes, challenge the positions of some of the established health-care organizations as well as the marketers of health information. Eternal vigilance is a small price to pay for health. — Michael Jorrin (aka DocGumshoe) Michael Jorrin is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

Miracles Redux

The last time Dr Al Sears crossed our path, his banner headline was that President Obama, “the most corrupt president in U. S. history,” issued a “Death Order” in 2016 that “could result in the needless deaths of 1.3 million American seniors this year.”   That “Death Order” consisted in the appointment of Robert Califf, […]

What’s New this Summer?

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends.  He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]

Bulletins from the Cardiac Front

[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month.  He does not typically write specifically about investments, but does write about publicly traded companies and their drugs, and has agreed to our trading […]

Antibiotic Resistance: What’s Happening?

[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

The Miracle Cures Keep Coming 

[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

End of Winter Miscellany

[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]

Recent Author Comments

On In Defense of the Egg
... but without Investing Gumshoe there would be no Doc Gumshoe![...]
On In Defense of the Egg
I'm gratified by the volume and tone of the comments, thanks very much. Can't respond to any in particular today - have to go to a funeral & then the dress rehearsal for our chorus's Saturday concert. I'll make a note of the many suggestions for furthe[...]
On What's Curzio's "The End of Heart Disease" Stock and its "One Simple Device?"
Oh, my! Omron also makes a fairly reliable BP device, surely more accurate that a watch, for about seventy bucks. A continuous BP device is perhaps valuable in a very few people, but BP should be measured at rest for the readings to have any value, sin[...]
On Blanco's " $2 Trillion 'Bio-Switch'" Stock -- he says it's "Hailed as Miracle Drug for 3 Killer Diseases"
Many pharm outfits - Novartis, for one - are researching epigenetics, which is indeed a promising field. There will certainly be many drugs based on that mechanism. Does Resverlogix have an inside track? Just possibly.[...]
On Rapid Response: The Israeli Cure for All Cancers? And a Postscript on Opioids
As always, thanks for the comments. I can see that I have my work cut out - several interesting suggestions to look into. Best to all, Michael Jorrin (AKA Doc Gumshoe[...]
On Looking Backward – And a Peek in the Other Direction
I can't say whether it would be "profitable" to look into either of those two enterprises. It's very early days for both. MRI imaging has been combined with precisely targeted radiation therapy for several years and has led to great improvements in out[...]
On Looking Backward – And a Peek in the Other Direction
I've never heard of that particular one, but "a cure for every cancer" is exceedingly unlikely. A tiny bit of digging came up with this, published in Forbes: “As someone with 10 years of molecular biology and medical experience, I strongly suspect th[...]
On Skousen's "American X" Company knows how to kill a $40 billion disease... what is it?
Pfizer had four new drug approvals in 2018 and is looking quite strong looking forward, in addition to which they have many irons in the fire. I can't see that Dekavil is going to make a huge difference. And as for turning off the part of the immune re[...]
On Ketamine: Menace or Miracle?
Sorry about your experience! Were you already on a pain killer when they added the ketamine? There is clearly a lot more to be learned about the whole subject.[...]
On Ketamine: Menace or Miracle?
Not being a bona fide MD I can't comment on whether your wife would benefit from ketamine. But I would advise against buying it on the open market without a prescription. Getting the right dose of any drug is crucial. Good luck in your hunt for a doc[...]
On Trying to Make Sense of Puzzling Health-Care News
You are correct. In terms of morphine equivalent, hydromorphone is more potent than oxycodone, but oxycodone may take effect more rapidly. Percocent is oxycodone compouinded with acetominophen, which limits the dosage. Thanks & best, MJ[...]
On Two More Miracle Cures: An Honest Assessment, I Hope!
I'll take a look at ChromaDex & Tru Niagen. Thanks for the comments & best to all.[...]
On Cancer Treatment 2018: Looking Towards the Future
Sorry not to respond sooner - I've been away, visiting my 94-year-old mother-in-law who is doing pretty well all things considered. I'll go through your comments & respond in some detail as soon as I can manage. And I'll put kidney disease into the ho[...]
On Getting Back to You: Responses to Comments on Cancer 2018
Elbert, I don't comment on stocks per se - too many things other than the actual benefit (or lack of benefit) of their products affect their performance. Cel Sci's offering is a leukocyte interleukin, which could well have cancer-fighting properties, as [...]
On Getting Back to You: Responses to Comments on Cancer 2018
Sorry if I was less than clear. All 2200 men had a diagnosis of prostate cancer and all chose active surveillance at the time of diagnosis. The 432 men were those who were under 60 years old at the start of the study, and they were studied as a subgrou[...]
On Cancer: The Lay of the Land in 2018
Many highly interesting comments for which many thanks. I will attempt to respond (& perhaps actually answer) to as many as possible, all in one entry. Briefly, yes, I am working on Delta 8 right now & will follow up with a look at what's happening wit[...]
On Solved: "WARNING: 'Golden Pill' May Make You Rich… " tease
Since blood pressure and cholesterol-lowering drugs have become cheap and common, heart disease mortality has plummeted, and it ain't because lots of people have swopped eating steak for Brazil nuts. The newer alternative cholesterol-lowering drugs will [...]
On Late Summer Pickings: September 2018
I am always pleased and entertained to see the variety of comments in reponse to my contributions to Gumshoe World. At the same time, I find it really difficult to respond to comments that proclaim a huge conspiracy between pharmaceutical companies, the [...]
On Alzheimer’s Disease 2018: The Lay of the Land
Yes, I have written about Parkinson's, but not for Doc Gumshoe - more for the professional medical audience to alert them to recent developments. Parkinson's and Alzheimer's do have some features in common, but Parkinson's is quite distinct in how it aff[...]
On Alzheimer’s Disease 2018: The Lay of the Land
Many interesting comments in response to that Alzheimer’s piece. I’ll try to respond to as many as I can. And many, many thanks for the comments. First, thank you for suggesting those books – I’ll try to do a bit more homework before I comme[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch